Illumina/Agilent deal raises genome sequencing ante

Agilent and Illumina recently announced a comarketing agreement aimed to help the two technology leaders further penetrate the $3 billion genomics space. According to the companies, Agilent's SureSelect Target Enrichment System will allow researchers to home in on small variations in large gene sequ...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research

Researchers significantly improve sequencing accuracy of Oxford Nanopore's technology

News Commentary | January 20, 2021

University of British Columbia researchers reported reducing sequencing errors using the portable MinION technology as well as PacBio's circular consensus sequencing from 10% to 0.005% through the application of a bar coding system. The application of unique molecular identifiers (UMIs) to ... Not part of subscription

Oxford Nanopore prepares for a $3 billion IPO

News Commentary | April 01, 2021

Oxford Nanopore's nanopore technology has come into the limelight since the COVID‑19 outbreak. Since then, it has supported scientists in over 85 countries in tracking the emergence of new mutant variants. This field validation and its ability to overcome various technical hurdles sets the stage for... To read more, click here.

Human Genomics

Technology | August 25, 2021

The sequencing, analysis, and interpretation of the human genome, which leads to therapeutic, diagnostic, and wellness applications. Not part of subscription